Camillo Porta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Camillo Porta has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Laura Cosmai
Division of Nephrology, A.S.S.T. Santi Paolo e Carlo, San Carlo Borromeo Hospital, Milan, Italy
2 shared publications- Anna Kornakiewicz
Department of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland
1 shared publication - Anna Malgorzata Czarnecka
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
1 shared publication Axel Bex
Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands
1 shared publicationBradley C. Leibovich
Department of Urology, Mayo Clinic, Rochester, MN, USA
1 shared publication- Cezary Szczylik
Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland
1 shared publication
Latest Publications
- 1 October 2019
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (10) , 1332-1334
Renal cell carcinoma treatment after first-line combinations
- 1 October 2019
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (10) , 1332-1334
Renal cell carcinoma treatment after first-line combinations
- 26 March 2019
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 15 (7) , 423-433
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Approximately 70% of cases of kidney cancer are localized or locally advanced at diagnosis. Among patients who undergo surgery for these cancers, 30–35% will eventually develop potentially fatal metachronous distant metastases. Effective adjuvant treatments are urgently needed to reduce the risk of recurrence of kidney cancer and of dying of metastatic disease. To date, almost all of the tested adjuvant agents have failed to demonstrate any benefit. Only two trials of an autologous renal tumour cell vaccine and of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor sunitinib have shown positive results, but these have been criticized for methodological reasons and conflicting data, respectively. The results of two additional trials of targeted agents as adjuvant therapies have not yet been published. Novel immune checkpoint inhibitors are promising approaches to adjuvant therapy in kidney cancer, and a number of trials are now underway. An important component of the management of patients with kidney cancer, particularly those who undergo radical resection for localized renal cell carcinoma, is the preservation of kidney function to reduce morbidity and mortality. The optimal management of these patients therefore requires a multidisciplinary approach involving nephrologists, oncologists, urologists and pathologists.
- 26 March 2019
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 15 (7) , 423-433
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Approximately 70% of cases of kidney cancer are localized or locally advanced at diagnosis. Among patients who undergo surgery for these cancers, 30–35% will eventually develop potentially fatal metachronous distant metastases. Effective adjuvant treatments are urgently needed to reduce the risk of recurrence of kidney cancer and of dying of metastatic disease. To date, almost all of the tested adjuvant agents have failed to demonstrate any benefit. Only two trials of an autologous renal tumour cell vaccine and of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor sunitinib have shown positive results, but these have been criticized for methodological reasons and conflicting data, respectively. The results of two additional trials of targeted agents as adjuvant therapies have not yet been published. Novel immune checkpoint inhibitors are promising approaches to adjuvant therapy in kidney cancer, and a number of trials are now underway. An important component of the management of patients with kidney cancer, particularly those who undergo radical resection for localized renal cell carcinoma, is the preservation of kidney function to reduce morbidity and mortality. The optimal management of these patients therefore requires a multidisciplinary approach involving nephrologists, oncologists, urologists and pathologists.
- 1 March 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (S1) , S15
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
- 1 March 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (S1) , S15
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
- 25 January 2019
- Published by Wolters Kluwer Health in Hepatology
- Vol. 70 (1) , 429-430
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient
- 25 January 2019
- Published by Wolters Kluwer Health in Hepatology
- Vol. 70 (1) , 429-430
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient
- Open Access
- 31 December 2018
- Published by Springer Nature in Cytotechnology
- Vol. 71 (1) , 149-163
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells
Novel experimental conditions of cancer cell line culture have evolved throughout the recent years, with significantly growing interest in xeno-free, serum-free and three-dimensional culture variants. The choice of proper culture media may enable to mimic tumor microenvironment and promotion of cancer stem cells proliferation. To assess whether stem-like phenotype inducing media may be applied in renal cancer stem cell research, we performed a widespread screening of 13 cell culture media dedicated for mesenchymal cells, stem cells as well as mesenchymal stem cells. We have also screened extracellular matrix compounds and selected optimal RCC 3D—ECM supported culture model. Our results revealed that 786-O as well as HKCSCs cell line cultures in xeno-free media (NutriStem/StemXvivo) and laminin coated plates provide a useful tool in RCC cancer biology research and at the same time enable effective drug toxicity screening. We propose bio-mimic 3D RCC cell culture model with specific low-serum and xeno-free media that promote RCC cell viability and stem-like phenotype according to the tested genes encoding stemness factors including E-cadherin, N-cadherin, HIF1, HIF2, VEGF, SOX2, PAX2 and NESTIN.
- 31 December 2018
- Published by Springer Nature in Cytotechnology
- Vol. 71 (1) , 149-163
Open AccessDevelopment of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells
Novel experimental conditions of cancer cell line culture have evolved throughout the recent years, with significantly growing interest in xeno-free, serum-free and three-dimensional culture variants. The choice of proper culture media may enable to mimic tumor microenvironment and promotion of cancer stem cells proliferation. To assess whether stem-like phenotype inducing media may be applied in renal cancer stem cell research, we performed a widespread screening of 13 cell culture media dedicated for mesenchymal cells, stem cells as well as mesenchymal stem cells. We have also screened extracellular matrix compounds and selected optimal RCC 3D—ECM supported culture model. Our results revealed that 786-O as well as HKCSCs cell line cultures in xeno-free media (NutriStem/StemXvivo) and laminin coated plates provide a useful tool in RCC cancer biology research and at the same time enable effective drug toxicity screening. We propose bio-mimic 3D RCC cell culture model with specific low-serum and xeno-free media that promote RCC cell viability and stem-like phenotype according to the tested genes encoding stemness factors including E-cadherin, N-cadherin, HIF1, HIF2, VEGF, SOX2, PAX2 and NESTIN.